Statin use vs. average non-HDL cholesterol levels in Turkmenistan

Turkmenistan: Statin use vs. average non-HDL cholesterol levels was 3.3 in 2018. ▬ Flat

Latest (2018)
3.3
Change on year
unchanged
World rank
95th
of 191 countries
All-time high
3.4
in 1980
All-time low
3.3
in 1989
Years of data
39
1980–2018

Statin use vs. average non-HDL cholesterol levels in Turkmenistan, 1980–2018

01231980199920181980: 3.41981: 3.41982: 3.41983: 3.41984: 3.41985: 3.41986: 3.41987: 3.41988: 3.41989: 3.31990: 3.31991: 3.31992: 3.31993: 3.31994: 3.31995: 3.31996: 3.31997: 3.31998: 3.31999: 3.32000: 3.32001: 3.32002: 3.32003: 3.32004: 3.32005: 3.32006: 3.32007: 3.32008: 3.32009: 3.32010: 3.32011: 3.32012: 3.32013: 3.32014: 3.32015: 3.32016: 3.32017: 3.32018: 3.3

Source: World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.

Analysis

The most recent figure for statin use vs. average non-hdl cholesterol levels in Turkmenistan is 3.3, measured in 2018. That is the lowest value across all 39 years on record.

Compared with earlier readings it is unchanged over ten years.

Over the whole period, statin use vs. average non-hdl cholesterol levels in Turkmenistan peaked at 3.4 in 1980 and was at its lowest, 3.3, in 1989.

Turkmenistan ranks 95th of 191 countries on this measure, in the middle of the range.

Averages by decade

DecadeAverage LowestHighest Years
1980s 3.39 3.3 3.4 10
1990s 3.3 3.3 3.3 10
2000s 3.3 3.3 3.3 10
2010s 3.3 3.3 3.3 9

Countries ranked near Turkmenistan

  1. 95 Algeria 3.3 compare
  2. 95 Azerbaijan 3.3 compare
  3. 95 Bahrain 3.3 compare
  4. 95 Barbados 3.3 compare
  5. 95 Bolivia 3.3 compare
  6. 95 Bosnia and Herzegovina 3.3 compare
  7. 95 Cambodia 3.3 compare
  8. 95 China 3.3 compare
  9. 95 Cuba 3.3 compare
  10. 95 Egypt 3.3 compare
  11. 95 Ghana 3.3 compare
  12. 95 Kiribati 3.3 compare
  13. 95 Laos 3.3 compare
  14. 95 Luxembourg 3.3 compare
  15. 95 Marshall Islands 3.3 compare
  16. 95 Netherlands 3.3 compare
  17. 95 Spain 3.3 compare
  18. 95 Sri Lanka 3.3 compare
  19. 95 Suriname 3.3 compare
  20. 95 Turkey 3.3 compare
  21. 95 United Kingdom 3.3 compare
  22. 95 United States 3.3 compare

See the full ranking of 191 places →

More reference data data for Turkmenistan

All data for Turkmenistan →

Frequently asked questions

What is statin use vs. average non-hdl cholesterol levels in Turkmenistan?
Statin use vs. average non-hdl cholesterol levels in Turkmenistan was 3.3 in 2018, according to World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data.
What is the highest statin use vs. average non-hdl cholesterol levels recorded in Turkmenistan?
The highest recorded value was 3.4 in 1980.
What is the lowest statin use vs. average non-hdl cholesterol levels recorded in Turkmenistan?
The lowest recorded value was 3.3 in 1989.
How does Turkmenistan rank for statin use vs. average non-hdl cholesterol levels?
Turkmenistan ranks 95th out of 191 countries with data for 2018.
Is statin use vs. average non-hdl cholesterol levels rising or falling in Turkmenistan?
Over the last ten years it is unchanged. The long-run trend across the full record is flat.
Where does this Turkmenistan data come from?
The figures come from World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as part of Statin use vs. average non-HDL cholesterol levels. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 39 observations, free to reuse under CC BY 4.0 (Our World in Data).

About this data

Indicator
Statin use vs. average non-HDL cholesterol levels
Source
World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
191 places, 7,449 data points, 1980–2018
Last refreshed

The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.